Trial Profile

A Randomized Controlled, Multicenter, Open, Seamless Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 25 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Lenvatinib (Primary) ; Oxaliplatin (Primary) ; Toripalimab (Primary) ; Capecitabine
Indications Cholangiocarcinoma
Focus Therapeutic Use

21 Aug 2025 Status changed from recruiting to active, no longer recruiting.
21 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
21 Feb 2025 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com